Dr. David W. Victor III, M.D.
Hepatology (Transplant Hepatology Physician)
- Medicare participating
At a glance
- Medical school
- University of Kentucky College of Medicine (2005)
- Years since graduation
- 21
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 475
Licensed in Texas since 2013, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Medical school: University of Kentucky College of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Transplant Hepatology Physician primary
TX license P7593 (first issued 2013; active) -
Gastroenterology Physician
MD license D0071978 · TX license P7593 (first issued 2013; active) -
Hepatology Physician
TX license P7593 (first issued 2013; active) -
Internal Medicine Physician
LA license 201516
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Houston Methodist Hospital Houston, TX
- Houston Methodist Sugarland Hospital Sugar Land, TX
- Houston Methodist the Woodlands Hospital The Woodlands, TX
- Houston Methodist West Hospital Houston, TX
- Houston Methodist Clear Lake Hospital Nassau Bay, TX
Medical groups
- Tmh Physician Associates PLLC (1,690 clinicians)
- Houston Methodist Specialty Physicians (1,528 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 475
- Services billed
- 1,166
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 459 | 268 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 316 | 99 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 83 | 43 |
| New patient office or other outpatient visit, 45-59 minutes | 45 | 45 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 45 | 44 |
| Established patient office or other outpatient visit, 40-54 minutes | 31 | 28 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 17 | 16 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 13 | 13 |
| Established patient office or other outpatient visit, 10-19 minutes | 12 | 11 |
| New patient office or other outpatient visit, 60-74 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Xifaxan (rifaximin) Other prescribers in Houston, TX | 222 |
| Ursodiol Other prescribers in Houston, TX | 221 |
| Spironolactone Other prescribers in Houston, TX | 103 |
| Furosemide Other prescribers in Houston, TX | 80 |
| Azathioprine Other prescribers in Houston, TX | 66 |
| Entecavir | 57 |
| Lactulose Other prescribers in Houston, TX | 54 |
| Carvedilol Other prescribers in Houston, TX | 47 |
| Constulose (lactulose) Other prescribers in Houston, TX | 32 |
| Ocaliva (obeticholic acid) | 32 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 17 companies reported 114 payments worth $105,729 in total to this clinician.
| Madrigal Pharmaceuticals | $47,432 |
|---|---|
| Ipsen Biopharmaceuticals, Inc | $21,782 |
| Intercept Pharmaceuticals, Inc. | $17,463 |
| Gilead Sciences, Inc. | $12,182 |
| Novo Nordisk Inc | $4,064 |
| Novo Nordisk As | $1,965 |
| Janssen Biotech, Inc. | $269 |
| AbbVie Inc. | $168 |
| Compensation for services other than consulting (speaking, faculty) | $66,879 |
|---|---|
| Consulting Fee | $23,685 |
| Speaking at a medical education program | $6,480 |
| Food and Beverage | $4,425 |
| Travel and Lodging | $4,259 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc Feb 8, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $8,836 |
| Madrigal Pharmaceuticals Sep 2, 2025 | Consulting Fee REZDIFFRA · LIVER DISEASE | $7,050 |
| Intercept Pharmaceuticals, Inc. Mar 29, 2025 | Consulting Fee OCALIVA · Hepatology / Gastroenterology | $5,400 |
| Madrigal Pharmaceuticals Jul 18, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $5,288 |
| Ipsen Biopharmaceuticals, Inc Sep 4, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $5,049 |
| Madrigal Pharmaceuticals Oct 15, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $4,935 |
| Intercept Pharmaceuticals, Inc. Jul 18, 2025 | Consulting Fee OCALIVA · Hepatology / Gastroenterology | $4,320 |
| Madrigal Pharmaceuticals Jan 27, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $3,878 |
| Madrigal Pharmaceuticals Jul 29, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $3,878 |
| Madrigal Pharmaceuticals Aug 7, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $3,878 |
All 43 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Gilead Sciences, Inc. Dec 9, 2025 | Compensation for services other than consulting (speaking, faculty) Livdelzi · INFLAM Company’s description;4269551;AHM;10161673 | $3,030 |
| Madrigal Pharmaceuticals Dec 4, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $3,878 |
| Gilead Sciences, Inc. Nov 11, 2025 | Compensation for services other than consulting (speaking, faculty) Epclusa · HCV Company’s description;4258154;AHM;10161673 | $3,790 |
| Madrigal Pharmaceuticals Oct 15, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $4,935 |
| Madrigal Pharmaceuticals Oct 15, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to BRYAN, TX · in-kind | $1,008 |
| Ipsen Biopharmaceuticals, Inc Oct 10, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $1,836 |
| Ipsen Biopharmaceuticals, Inc Sep 4, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $5,049 |
| Madrigal Pharmaceuticals Sep 2, 2025 | Consulting Fee REZDIFFRA · LIVER DISEASE | $7,050 |
| Ipsen Biopharmaceuticals, Inc Aug 25, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $1,836 |
| Madrigal Pharmaceuticals Aug 21, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to CHICAGO, IL · in-kind | $391 |
| Madrigal Pharmaceuticals Aug 21, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to CHICAGO, IL · in-kind | $250 |
| Madrigal Pharmaceuticals Aug 21, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to CHICAGO, IL · in-kind | $221 |
| Madrigal Pharmaceuticals Aug 21, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to CHICAGO, IL | $47.00 |
| Madrigal Pharmaceuticals Aug 7, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $3,878 |
| Madrigal Pharmaceuticals Jul 29, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $3,878 |
| Madrigal Pharmaceuticals Jul 18, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $5,288 |
| Intercept Pharmaceuticals, Inc. Jul 18, 2025 | Consulting Fee OCALIVA · Hepatology / Gastroenterology | $4,320 |
| Madrigal Pharmaceuticals Jul 18, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to DALLAS, TX · in-kind | $317 |
| Madrigal Pharmaceuticals Jul 18, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to DALLAS, TX · in-kind | $244 |
| Madrigal Pharmaceuticals Jul 18, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to DALLAS, TX · in-kind | $232 |
| Madrigal Pharmaceuticals Jul 17, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $1,763 |
| Intercept Pharmaceuticals, Inc. Jul 14, 2025 | Speaking at a medical education program OCALIVA · Hepatology / Gastroenterology | $3,240 |
| Intercept Pharmaceuticals, Inc. Jun 24, 2025 | Speaking at a medical education program OCALIVA · Hepatology / Gastroenterology | $3,240 |
| Gilead Sciences, Inc. Jun 4, 2025 | Consulting Fee Livdelzi · INFLAM Company’s description;4147927;VEM US;10161673 | $1,020 |
| Gilead Sciences, Inc. May 28, 2025 | Compensation for services other than consulting (speaking, faculty) Epclusa · HCV Company’s description;4113537;AHM;10161673 | $3,790 |
| Novo Nordisk As May 11, 2025 | Consulting Fee Multiple Therapeutic Areas | $983 |
| Ipsen Biopharmaceuticals, Inc May 1, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $2,754 |
| Novo Nordisk Inc Apr 28, 2025 | Consulting Fee Multiple Therapeutic Areas | $1,638 |
| Intercept Pharmaceuticals, Inc. Mar 29, 2025 | Consulting Fee OCALIVA · Hepatology / Gastroenterology | $5,400 |
| Intercept Pharmaceuticals, Inc. Mar 29, 2025 | Travel and Lodging OCALIVA · Hepatology / Gastroenterology · travel to Chicago, IL | $300 |
| Intercept Pharmaceuticals, Inc. Mar 29, 2025 | Travel and Lodging OCALIVA · Hepatology / Gastroenterology · travel to Chicago, IL · in-kind | $49.00 |
| Intercept Pharmaceuticals, Inc. Mar 28, 2025 | Travel and Lodging OCALIVA · Hepatology / Gastroenterology · travel to Chicago, IL · in-kind | $257 |
| Intercept Pharmaceuticals, Inc. Mar 28, 2025 | Travel and Lodging OCALIVA · Hepatology / Gastroenterology · travel to Chicago, IL · in-kind | $204 |
| Madrigal Pharmaceuticals Mar 24, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $1,763 |
| Novo Nordisk As Mar 13, 2025 | Consulting Fee Multiple Therapeutic Areas | $983 |
| Madrigal Pharmaceuticals Mar 12, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $2,820 |
| Madrigal Pharmaceuticals Mar 11, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $1,763 |
| Novo Nordisk Inc Feb 17, 2025 | Consulting Fee Multiple Therapeutic Areas | $2,293 |
| Ipsen Biopharmaceuticals, Inc Feb 8, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $8,836 |
| Ipsen Biopharmaceuticals, Inc Feb 8, 2025 | Travel and Lodging IQIRVO · Rare Disease · travel to Dallas, TX · in-kind | $441 |
| Ipsen Biopharmaceuticals, Inc Feb 8, 2025 | Travel and Lodging IQIRVO · Rare Disease · travel to Dallas, TX · in-kind | $299 |
| Madrigal Pharmaceuticals Jan 27, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $3,878 |
| Madrigal Pharmaceuticals Jan 17, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $2,115 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $98,367 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
Madrigal Pharmaceuticals · Active, not recruiting · NCT04951219 - Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)
Ipsen Bioscience Inc. · Active, not recruiting · NCT04526665 - Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132)
Bausch Health US, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.